A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer.

Wenqiang Wu, Chengmiao Luo, Chunhui Zhu, Zhengyan Cai, Jianyong Liu

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenqiang WuChina State Institute of Pharmaceutical Industry, Pudong New Area, Shanghai 201203, China.

Chengmiao LuoKey Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry, Fuzhou University, Fuzhou 350108, China.

Chunhui ZhuKey Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry, Fuzhou University, Fuzhou 350108, China.

Zhengyan CaiChina State Institute of Pharmaceutical Industry, Pudong New Area, Shanghai 201203, China.

Jianyong LiuKey Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry, Fuzhou University, Fuzhou 350108, China.ORCID 0000-0003-3349-6623

Funding

the Natural Science Foundation of China 214071033the Natural Science Foundation of China 82374081the Natural Science Foundation of Fujian Province, China 2020J01440

6 · The paper itself

Abstract

Photodynamic Therapy (PDT) is recognized for its exceptional effectiveness as a promising cancer treatment method. However, it is noted that overexposure to the dosage and sunlight in traditional PDT can result in damage to healthy tissues, due to the low tumor selectivity of currently available photosensitizers (PSs). To address this challenge, we introduce herein a new strategy where the small molecule-targeted agent, erlotinib, is integrated into a boron dipyrromethene (BODIPY)-based PS to form conjugate

Indexed as

Erlotinib HydrochlorideLiver NeoplasmsPhotochemotherapyPhotosensitizing AgentsPorphobilinogenAnimalsBoron CompoundsHep G2 CellsHumansMiceBoron CompoundsdipyrrometheneErlotinib HydrochloridePhotosensitizing AgentsPorphobilinogenBODIPYerlotinibphotodynamic therapyphotosensitizerreactive oxygen species

Identifiers

PMID38928126

DOI10.3390/ijms25126421

PMCPMC11203698

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.